Novus Worldwide, Inc. publicizes it has accomplished the acquisition of U.S.-based enzyme firm BioResource Worldwide, Inc. (BRI). Beneath the phrases of the settlement, NOVUS turns into the proprietor of all BRI’s merchandise and mental property and takes management of the corporate’s services.

“This transfer will permit us to serve our clients higher and develop our innovation pipeline additional,” says NOVUS President & CEO Dan Meagher. “Enzymes are very important instruments for producers to make sure animal well being and well-being and assist ship on-farm profitability. We’re very excited to supply our clients extra choices, in addition to aspire to develop new feed components.”

The connection between the 2 corporations isn’t new. NOVUS has partnered with BRI since 2008 to fabricate its protease product, CIBENZA^® Enzyme Feed Additive. Meagher says having full possession and management of the product line and the choice to develop NOVUS’ portfolio past protease enzymes is a pure match within the firm’s long-term strategic plans.

“As a pacesetter in clever diet, NOVUS’ priorities embrace investing additional in practical proteins and the intestine well being phase, rising our portfolio, and attaining stronger management of our provide chain,” he says. “Together with supporting these objectives, buying BRI additionally will increase our capabilities to develop revolutionary options within the fermentation house.”

BRI’s merchandise embrace Versazyme^® protease feed additive, Xylamax^® xylanase feed enzyme, Dymanase^® mannanase enzyme, Phytamax^® granulated, thermostable, microbial 6-phytase enzyme; and EnzaPro^® enzyme and direct-fed microbials, amongst others.

BRI’s co-founder and CEO Giles Shih, Ph.D., says the acquisition and tapping into the data of workers in each BRI and NOVUS permits for the continued development of the corporate he helped create 25 years in the past.

“We’re tremendous excited concerning the future the place BRI’s merchandise and folks mix forces with the worldwide attain and deep trade data NOVUS brings to the feed additive house,” Shih says. “This deal will not be certainly one of happenstance. Our two corporations have labored carefully collectively since 2008 to launch the primary era of heat-stable protease feed enzymes and form how they’re developed, marketed, and optimized so as to add worth to clients worldwide. This acquisition will allow NOVUS to innovate the subsequent era of proteases and enzymes that can do much more, from selling intestine well being to selling the underside line.”

Together with BRI’s present product portfolio, NOVUS additionally takes over the corporate’s services in North Carolina within the U.S.

Meagher says continuity is vital for present BRI clients and they need to expertise “enterprise as typical” throughout the integration course of.

March 5, 2024 – NOVUS